AIM AIM ImmunoTech Inc.

NYSE aimimmuno.com


$ 1.68 $ 0.01 (0.6 %)    

Friday, 07-Nov-2025 15:59:46 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 1.68
$ 1.63
$ 1.57 x 1
$ 1.68 x 200
$ 1.57 - $ 1.68
$ 0.06 - $ 20.35
73,151
na
4.55M
$ -1.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-aim-immunotech-lowers-price-target-to-24

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $150 t...

 aim-immunotech-has-been-granted-european-patent-number-ep4096675-titled-compositions-for-treating-long-covid

https://register.epo.org/application?number=EP21818146

 aim-immunotech-says-jitc-publishes-new-peer-reviewed-article-providing-evidence-of-combination-effect-of-aims-drug-ampligen-and-interferon-alpha-on-tumor-growth-and-subsequent-subject-survival

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Journal for ImmunoTherapy of C...

 aim-immunotech-q2-eps-368-beats-800-estimate-sales-2500k-miss-10000k-estimate

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(3.68) per share which beat the analyst consensus estimate of $(8.00) b...

 aim-immunotech-announces-that-its-drug-ampligen-will-be-featured-in-four-presentations-at-upcoming-5th-annual-marie-sklodowska-curie-symposium-on-cancer-research-and-care-in-warsaw-poland

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the strong clinical successes in o...

 aim-immunotech-announces-company-update-including-mid-year-report-of-ampligen-in-combination-with-astrazenecas-imfinzi-for-treatment-of-pancreatic-cancer-demonstrating-signs-of-both-no-significant-toxicity-and-superior-pfs-and-oscompany-also-bolstered-cash-position-to-fund-operations-for-12-months

Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (d...

 why-is-micro-cap-aim-immunotech-stock-surging

AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION